Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ORIC

ORIC - ORIC Pharmaceuticals Inc Stock Price, Fair Value and News

7.14USD-0.09 (-1.24%)Market Closed

Market Summary

ORIC
USD7.14-0.09
Market Closed
-1.24%

ORIC Stock Price

View Fullscreen

ORIC RSI Chart

ORIC Valuation

Market Cap

481.4M

Price/Earnings (Trailing)

-4.73

Price/Sales (Trailing)

10.5K

Price/Free Cashflow

-5.01

ORIC Price/Sales (Trailing)

ORIC Profitability

Return on Equity

-30.96%

Return on Assets

-29.01%

Free Cashflow Yield

-19.94%

ORIC Fundamentals

ORIC Revenue

Revenue (TTM)

60.0K

ORIC Earnings

Earnings (TTM)

-101.8M

Earnings Growth (Yr)

-4.45%

Earnings Growth (Qtr)

11.72%

Breaking Down ORIC Revenue

Last 7 days

-4.0%

Last 30 days

-16.5%

Last 90 days

-46.9%

Trailing 12 Months

10.0%

How does ORIC drawdown profile look like?

ORIC Financial Health

Current Ratio

21.31

ORIC Investor Care

Shares Dilution (1Y)

49.52%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220000
2021060.0K00

Tracking the Latest Insider Buys and Sells of ORIC Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
kunkel lori anne
acquired
76,875
3.75
20,500
-
Mar 06, 2024
chacko jacob
sold
-648,380
16.2095
-40,000
president and ceo
Feb 07, 2024
chacko jacob
sold
-320,186
12.295
-26,042
president and ceo
Feb 06, 2024
chacko jacob
sold
-169,160
12.1192
-13,958
president and ceo
Dec 15, 2023
piscitelli dominic
sold
-
-
-14,042
chief financial officer
Dec 15, 2023
piscitelli dominic
sold
-45,338
8.5835
-5,282
chief financial officer
Dec 15, 2023
chacko jacob
acquired
-
-
38,667
president and ceo
Dec 15, 2023
chacko jacob
sold
-124,813
8.5847
-14,539
president and ceo
Dec 15, 2023
multani pratik s
acquired
-
-
14,042
chief medical officer
Dec 15, 2023
multani pratik s
sold
-45,350
8.5859
-5,282
chief medical officer

1–10 of 50

Which funds bought or sold ORIC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
104
119,678
177,678
0.02%
May 20, 2024
Virtu Financial LLC
new
-
225,000
225,000
0.02%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-324,520
-
-%
May 16, 2024
COMERICA BANK
sold off
-100
-12,254
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.93
-5,155
53,955
-%
May 15, 2024
DAFNA Capital Management LLC
sold off
-100
-669,732
-
-%
May 15, 2024
Prosight Management, LP
sold off
-100
-14,520,000
-
-%
May 15, 2024
Squarepoint Ops LLC
reduced
-33.33
-864
238,851
-%
May 15, 2024
VR Adviser, LLC
added
80.97
38,083,600
60,424,700
2.87%
May 15, 2024
Point72 Asset Management, L.P.
sold off
-100
-4,794,510
-
-%

1–10 of 47

Are Funds Buying or Selling ORIC?

Are funds buying ORIC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ORIC
No. of Funds

Unveiling ORIC Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
ecor1 capital, llc
8.9%
6,275,210
SC 13G/A
Feb 13, 2024
prosight management, lp
2.9%
1,578,263
SC 13G/A
Feb 13, 2024
alkeon capital management llc
6.6%
3,604,096
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
blackrock inc.
4.5%
2,995,032
SC 13G/A
Feb 06, 2024
millennium management llc
0.0%
0
SC 13G/A
Feb 01, 2024
venrock healthcare capital partners iii, l.p.
6.6%
4,428,385
SC 13G
Jan 30, 2024
viking global investors lp
5.9%
4e+06
SC 13G
Jan 29, 2024
blackrock inc.
5.7%
3,095,648
SC 13G

Recent SEC filings of ORIC Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 14, 2024
8-K
Current Report
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
May 06, 2024
8-K
Current Report
May 06, 2024
10-Q
Quarterly Report
Apr 24, 2024
DEFA14A
DEFA14A

Peers (Alternatives to ORIC Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.89
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.71
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

ORIC Pharmaceuticals Inc News

Latest updates
Defense World21 Jun 202412:20 pm
Defense World20 Jun 202401:33 pm

ORIC Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q32021Q32021Q2
Revenue---15.00
Operating Expenses39.2%25,69418,45621,057
  S&GA Expenses7.5%5,9715,5575,540
Net Income-34.7%-24,829-18,426-21,009
Net Income Margin-8.1%-1.52-1.40-1.52
Free Cashflow-59.4%-19,721-12,375-16,349
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets39.2%35125227429222724723826027529931426828429919220285.0094.0047.00
  Current Assets52.4%32421323226819321019923423924129326528029718919980.0090.0044.00
    Cash Equivalents141.0%56.0023.0026.0010459.0067.0029.0049.0011322624117010478.0062.0019779.0089.0043.00
  Net PPE-2.1%3.003.003.003.003.003.003.003.002.002.002.002.002.002.002.002.002.002.003.00
Liabilities-20.7%22.0028.0027.0023.0024.0025.0023.0023.0022.0026.0023.0010.008.009.007.006.005.006.004.00
  Current Liabilities-25.7%15.0020.0019.0015.0015.0015.0013.0012.0012.0015.0012.0010.008.009.007.006.005.005.003.00
Shareholder's Equity46.7%329224247269203222215237253273292258276290184195---
  Retained Earnings-5.7%-459-434-406-381-358-334-313-288-268-245-222-203-182-166-138-112-101-92.69-65.81
  Additional Paid-In Capital19.7%7896596546505615585305275225185144624594563233083.003.001.00
Shares Outstanding22.9%67.0055.0055.0055.0045.0045.0039.0039.0039.0039.0037.0037.00-------
Float----415---172---522---743---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-24.4%-30,186-24,270-19,645-21,145-20,628-15,329-19,320-17,776-22,718-16,284-12,142-16,214-14,901-17,825-9,580-9,584-8,279-7,148-5,360-5,494-5,531
  Share Based Compensation26.4%4,9583,9233,8643,8253,6143,1303,2934,0923,9453,4993,3973,2132,7441,6891,6811,381527442271190191
Cashflow From Investing-395.1%-61,86820,963-57,831-19,31312,77828,300-685-46,203-90,66035135,07282,36540,647-91,256-124,690-202189-56.00-219-393-100
Cashflow From Financing27500.4%125,03045331.0085,174-24,7931.0041516.0081348,586-28116.00125,496-341126,986-1,627-61.005,69849,92315,264
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ORIC Income Statement

2024-03-31
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 21,960$ 19,516
General and administrative7,0306,162
Total operating expenses28,99025,678
Loss from operations(28,990)(25,678)
Other income, net3,9791,733
Net loss(25,011)(23,945)
Other comprehensive income (loss):  
Unrealized gain or loss on investments(420)792
Comprehensive loss$ (25,431)$ (23,153)
Net loss per share, basic$ (0.37)$ (0.53)
Net loss per share, diluted$ (0.37)$ (0.53)
Weighted-average shares outstanding, basic67,349,55145,090,166
Weighted-average shares outstanding, diluted67,349,55145,090,166

ORIC Balance Sheet

2024-03-31
BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 56,360$ 23,384
Short-term investments260,418184,803
Prepaid expenses and other current assets7,3054,410
Total current assets324,083212,597
Long-term investments14,69426,852
Property and equipment, net2,8012,862
Other assets9,2089,696
Total assets350,786252,007
Current liabilities:  
Accounts payable2,988944
Accrued liabilities12,22219,514
Total current liabilities15,21020,458
Other long-term liabilities6,9317,461
Total liabilities22,14127,919
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 67,420,338 and 54,865,553 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively76
Additional paid-in capital788,738658,751
Accumulated deficit(459,938)(434,927)
Accumulated other comprehensive (loss) income(162)258
Total stockholders' equity328,645224,088
Total liabilities and stockholders' equity$ 350,786$ 252,007
ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEoricpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES89

ORIC Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for ORIC Pharmaceuticals Inc? What does ORIC stand for in stocks?

ORIC is the stock ticker symbol of ORIC Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ORIC Pharmaceuticals Inc (ORIC)?

As of Mon Jun 24 2024, market cap of ORIC Pharmaceuticals Inc is 481.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers.

What is the fair value of ORIC stock?

You can check ORIC's fair value in chart for subscribers. The fair value of ORIC Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ORIC Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORIC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ORIC Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ORIC is over valued or under valued. Whether ORIC Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ORIC Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORIC.

What is ORIC Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, ORIC's PE ratio (Price to Earnings) is -4.73 and Price to Sales (PS) ratio is 10.53 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORIC PE ratio will change depending on the future growth rate expectations of investors.